High-concentration biologic formulations: challenges, strategies, and emerging technologies for subcutaneous delivery
European Journal of Pharmaceutics and Biopharmaceutics · 2026-09 · 226 · 115178
DOI: 10.1016/j.ejpb.2026.115178 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026-09. Verfasst von Juan Ma. Beteiligte Einrichtung: Nona Biosciences (Shanghai) Co., Ltd., Shanghai, China. Electronic address: juan.ma@nonabio.com. Hauptthemen laut MEDLINE: Biological Products, Drug Delivery Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 204 Literaturangaben.
Abstract (Originalsprache)
The growing demand for subcutaneous (SC) self-administration of biotherapeutics, driven by the rising prevalence of chronic diseases and healthcare cost-containment pressures, has accelerated the development of high-concentration formulations (HCFs). However, protein concentrations exceeding 100 mg/mL introduce significant challenges, including solubility limitations, high viscosity, aggregation propensity, injectability constraints, and manufacturing complexities. This review systematically examines the primary obstacles in HCF development and highlights recent advances in formulation and process technologies. Key strategies include: (i) excipient-based viscosity reducers; (ii) hyaluronidase-enabled large-volume SC delivery; (iii) lyophilization for decoupling manufacturing from final concentration; (iv) spray drying platforms including SnapShot™ and XeriJect®; (v) electrostatic spray drying (Elektroject™ Hypercon™); (vi) Microglassification™ dehydration technology; and (vii) protein crystallization (Crystalomics®). Collectively, these innovations are reshaping the landscape of high-concentration biologic drug products, enabling the transition from intravenous to subcutaneous administration for a broader range of therapeutics. This review serves as a strategic guide for formulation scientists and drug developers engaged in next-generation subcutaneous biologics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nona Biosciences (Shanghai) Co., Ltd., Shanghai, China. Electronic address: juan.ma@nonabio.com.
Zitieren
APA
Ma, J. (2026). High-concentration biologic formulations: challenges, strategies, and emerging technologies for subcutaneous delivery. European Journal of Pharmaceutics and Biopharmaceutics, 226, 115178. https://doi.org/10.1016/j.ejpb.2026.115178
Vancouver
Ma J. High-concentration biologic formulations: challenges, strategies, and emerging technologies for subcutaneous delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2026;226:115178. doi:10.1016/j.ejpb.2026.115178
BibTeX
@article{Ma2026,
author = {Ma, Juan},
title = {High-concentration biologic formulations: challenges, strategies, and emerging technologies for subcutaneous delivery},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2026},
volume = {226},
pages = {115178},
doi = {10.1016/j.ejpb.2026.115178}
}
EUVIMED